Global Gastric Antral Vascular Ectasia (GAVE) Treatment Market Size, Share, and Trends Analysis Report – Industry Overview and Forecast to 2032

Gastric Antral Vascular Ectasia (GAVE) Treatment Market Size

• The global gastric antral vascular ectasia (GAVE) treatment market size was valued at USD 1.61 billion in 2024 and is expected to reach USD 2.12 billion by 2032, at a CAGR of 3.50% during the forecast period
• The market growth is largely fueled by increasing prevalence of gastrointestinal disorders and the rising demand for effective treatment options for gastric antral vascular ectasia (GAVE)
• Furthermore, advancements in endoscopic technologies, pharmacological therapies, and minimally invasive procedures are enhancing the efficiency and safety of GAVE treatments

Gastric Antral Vascular Ectasia (GAVE) Treatment Market Analysis

• The Gastric Antral Vascular Ectasia (GAVE) Treatment market is witnessing significant growth due to increasing prevalence of gastrointestinal bleeding disorders, rising awareness about early diagnosis, and the adoption of advanced treatment modalities
• The escalating demand for effective GAVE treatments is primarily fueled by advancements in endoscopic procedures, pharmacological interventions, and the growing focus on minimally invasive therapies.
• North America dominated the gastric antral vascular ectasia (GAVE) treatment market with the largest revenue share of 50% in 2024, supported by advanced healthcare infrastructure, widespread adoption of diagnostic and monitoring services, and strong presence of pharmaceutical companies investing in safer therapeutic alternatives. The U.S. remains the major contributor, driven by rising awareness campaigns on fluoroquinolone-associated risks, proactive pharmacovigilance programs, and early intervention strategies that enhance market demand
• Asia-Pacific is expected to be the fastest-growing region in the gastric antral vascular ectasia (GAVE) treatment market during the forecast period, with a CAGR of 9.1% from 2025 to 2032. Growth is fueled by increasing urbanization, rising disposable incomes, expansion of healthcare facilities offering specialized gastrointestinal disorder management, and growing awareness among patients and physicians regarding effective treatment options
• The endoscopy segment dominated the gastric antral vascular ectasia (GAVE) treatment market with a revenue share of 45.8% in 2024, driven by its minimally invasive nature, shorter recovery times, and proven efficacy in controlling bleeding in GAVE patients

Report Scope and Gastric Antral Vascular Ectasia (GAVE) Treatment Market Segmentation 

Gastric Antral Vascular Ectasia (GAVE) Treatment Market Trends

Advancements and Growing Adoption in Treatment Modalities

• A significant and accelerating trend in the global gastric antral vascular ectasia (GAVE) treatment market is the increasing adoption of advanced endoscopic therapies and pharmacological interventions, which are improving patient outcomes and reducing complications associated with traditional treatments
  • For instance, in March 2023, Takeda Pharmaceuticals reported progress in clinical trials of their new pharmacological agent targeting bleeding in GAVE patients, which demonstrated improved efficacy compared to conventional therapies
• Endoscopic modalities such as argon plasma coagulation (APC) and radiofrequency ablation (RFA) are witnessing higher adoption due to their minimally invasive nature, ability to control bleeding effectively, and suitability for repeated treatments. These approaches are becoming standard care in specialized gastroenterology centers globally
• Pharmacological advancements, including the use of hormonal and anti-angiogenic therapies, are being increasingly explored to complement endoscopic interventions, particularly in patients who are high-risk or unfit for repeated procedures. These therapies provide alternative or adjunctive treatment options, broadening the scope of GAVE management
• Healthcare providers are also emphasizing early diagnosis and proactive monitoring through improved diagnostic tools such as high-resolution endoscopy and imaging techniques, allowing timely intervention and reducing hospitalizations
• Rising awareness among patients and physicians about the risks of untreated GAVE, combined with educational initiatives and training programs for gastroenterologists, is further driving market growth
• Overall, the trend toward more effective, patient-centric, and minimally invasive treatment strategies is reshaping clinical practices and expanding the adoption of advanced GAVE treatment options across hospitals, specialty centers, and gastroenterology clinics worldwide

Gastric Antral Vascular Ectasia (GAVE) Treatment Market Dynamics

Driver

Growing Need Due to Rising Incidence and Awareness of GAVE

• The prevalence of gastric antral vascular ectasia (GAVE) is increasing globally, particularly among elderly patients, those with chronic liver disease, and individuals with other comorbidities such as renal failure or autoimmune disorders. This rising patient pool is creating a strong demand for effective and reliable treatment options
  • For instance, in April 2024, Takeda Pharmaceuticals reported progress in clinical trials for a novel pharmacological therapy designed to reduce gastrointestinal bleeding in GAVE patients, highlighting ongoing innovation by leading healthcare companies to address unmet medical needs
• Medical professionals are increasingly combining endoscopic interventions with pharmacological treatments to manage GAVE more effectively, resulting in improved patient outcomes and reduced complications such as anemia and chronic blood loss
• Awareness among physicians and patients regarding early diagnosis and proactive management of GAVE is growing, driven by updated clinical guidelines, educational campaigns, and professional training programs, which encourages timely interventions
• Advancements in minimally invasive endoscopic technologies and the development of targeted drug therapies are making treatments safer, more efficient, and widely accessible, contributing to the adoption of modern GAVE treatment protocols in hospitals, specialty care centers, and homecare settings
• Overall, the combination of increasing incidence, technological advancements, and heightened awareness of treatment options is fueling growth in the GAVE treatment market, encouraging investment and innovation across the healthcare sector

Restraint/Challenge

Concerns Regarding High Treatment Costs and Limited Accessibility

• The high cost of advanced endoscopic procedures and novel pharmacological therapies for GAVE continues to be a significant barrier to adoption. This is particularly evident in emerging markets or smaller healthcare institutions with limited budgets, where the affordability of such treatments can restrict patient access
• Many patients face challenges in reaching specialized centers with expertise in GAVE management. This limited accessibility often results in delayed or suboptimal treatment, negatively impacting overall clinical outcomes and patient quality of life.
• Insurance coverage limitations for innovative therapies further restrict patient access, especially in regions where reimbursement policies are still evolving. This can prevent timely intervention with advanced treatment options, despite their proven clinical benefits
• Healthcare providers must carefully balance the clinical advantages of advanced therapies with cost considerations, ensuring that limited resources are allocated efficiently to benefit the maximum number of patients. Strategic planning is essential to optimize both patient outcomes and institutional budgets
• Despite improvements in awareness and training, a shortage of experienced gastroenterologists and endoscopy specialists remains a challenge. This scarcity can slow the adoption of advanced treatment protocols, particularly in regions where specialist expertise is limited
• Overcoming these challenges through the expansion of healthcare infrastructure, initiatives to improve affordability, and enhanced clinical training will be critical. Such measures are essential for sustaining market growth and improving patient outcomes in the global GAVE treatment market

Gastric Antral Vascular Ectasia (GAVE) Treatment Market Scope

The market is segmented on the basis of treatment, end-users, and distribution channel.

• By Treatment

On the basis of treatment, the Gastric Antral Vascular Ectasia (GAVE) treatment market is segmented into surgery, medical therapy, and endoscopy. The endoscopy segment dominated the largest market revenue share of 45.8% in 2024, driven by its minimally invasive nature, shorter recovery times, and proven efficacy in controlling bleeding in GAVE patients. Endoscopic interventions, such as argon plasma coagulation, are widely preferred in hospitals and specialty clinics due to their high success rates and lower complication risks. The segment benefits from ongoing technological advancements in endoscopic devices, which improve precision, reduce patient discomfort, and allow repeated treatments if necessary. Endoscopy’s compatibility with outpatient procedures also increases patient throughput, making it a preferred choice among clinicians.

The medical therapy segment is expected to witness the fastest CAGR of 18.5% from 2025 to 2032, driven by increasing research into pharmacological agents for GAVE management, improved safety profiles, and the need for non-invasive treatment options. Growing awareness of adjunctive therapies, such as hormone-based treatments or vasoactive drugs, and their integration with standard care protocols is boosting adoption. Medical therapy is increasingly favored for patients unsuitable for surgery or those with comorbidities, creating a rising demand for effective drug-based interventions.

• By End-Users

On the basis of end-users, the Gastric Antral Vascular Ectasia (GAVE) treatment market is segmented into hospitals, homecare, specialty clinics, and others. The hospitals segment dominated the largest market revenue share of 52.3% in 2024, attributed to the presence of advanced endoscopic equipment, skilled gastroenterologists, and comprehensive patient care facilities. Hospitals are preferred for complex GAVE cases requiring continuous monitoring and multidisciplinary treatment approaches. High patient volumes, insurance coverage, and strong clinical infrastructure support the dominance of hospital-based treatments.

The specialty clinics segment is expected to witness the fastest CAGR of 16.9% from 2025 to 2032, driven by the rise of gastroenterology-focused centers offering advanced endoscopic procedures and personalized patient care. Specialty clinics provide flexibility in scheduling, shorter waiting times, and targeted treatments, which are appealing for patients with recurring GAVE or those seeking outpatient solutions. Increasing investments in private clinics, coupled with technological upgrades and physician expertise, are driving the growth of this segment.

• By Distribution Channel

On the basis of distribution channel, the Gastric Antral Vascular Ectasia (GAVE) treatment market is segmented into hospital pharmacy, retail pharmacy, online pharmacies, and others. The hospital pharmacy segment dominated the largest market revenue share of 48.7% in 2024, supported by the direct availability of endoscopic tools, therapeutic drugs, and post-procedure medications within hospitals. Hospital pharmacies ensure immediate access to treatment, facilitate integrated care, and provide high-quality, regulated pharmaceutical products.

The online pharmacy segment is expected to witness the fastest CAGR of 20.1% from 2025 to 2032, fueled by the growing trend of e-commerce in healthcare, increased patient preference for home delivery of medications, and expanding internet penetration. Online pharmacies offer convenience, competitive pricing, and easy access to rare or specialty medications for GAVE treatment, making them increasingly popular, particularly in urban and semi-urban regions. In addition, the integration of digital health platforms and telemedicine services is further enhancing the adoption of online pharmacies for GAVE treatment.

Gastric Antral Vascular Ectasia (GAVE) Treatment Market Regional Analysis

• North America dominated the gastric antral vascular ectasia (GAVE) treatment market with the largest revenue share of 50% in 2024, supported by advanced healthcare infrastructure, widespread adoption of diagnostic and monitoring services, and a strong presence of pharmaceutical companies investing in safer therapeutic alternatives
• The region benefits from well-established hospital networks, robust insurance coverage, and high patient awareness regarding gastrointestinal health
• This combination drives early diagnosis and proactive management of GAVE, boosting treatment adoption

U.S. Gastric Antral Vascular Ectasia (GAVE) Treatment Market Insight

The U.S. gastric antral vascular ectasia (GAVE) treatment market captured the largest revenue share within North America in 2024, driven by extensive pharmacovigilance programs, proactive awareness campaigns, and early intervention strategies that highlight fluoroquinolone-associated risks. Hospitals and specialty care centers are increasingly implementing advanced diagnostic and endoscopic treatment protocols, enhancing patient outcomes. Moreover, patient education and routine monitoring programs are improving early detection, which is a critical factor propelling market growth.

Europe Gastric Antral Vascular Ectasia (GAVE) Treatment Market Insight

The Europe gastric antral vascular ectasia (GAVE) treatment market is projected to expand at a substantial CAGR throughout the forecast period, fueled by growing awareness among gastroenterologists, the availability of advanced treatment facilities, and stringent clinical guidelines for gastrointestinal disorders. Urbanization and technological adoption in healthcare are increasing the demand for endoscopic and pharmacological interventions. European countries are also witnessing rising investments in specialized hospitals and research programs aimed at improving GAVE management.

U.K. Gastric Antral Vascular Ectasia (GAVE) Treatment Market Insight

The U.K. gastric antral vascular ectasia (GAVE) treatment market is anticipated to grow at a noteworthy CAGR during the forecast period, driven by increased public awareness about gastrointestinal bleeding disorders and the expansion of specialized gastroenterology centers. Government and private healthcare initiatives promoting early diagnosis, combined with patient-centric treatment programs, are encouraging higher adoption of advanced therapies. Additionally, the U.K.’s strong medical research infrastructure supports ongoing clinical studies and therapeutic advancements in GAVE management.

Germany Gastric Antral Vascular Ectasia (GAVE) Treatment Market Insight

The Germany gastric antral vascular ectasia (GAVE) treatment market is expected to expand at a considerable CAGR, propelled by a well-developed healthcare ecosystem, rising awareness of gastrointestinal disorders, and the demand for technologically advanced treatment solutions. Germany’s focus on research, innovation, and sustainable healthcare solutions encourages the adoption of endoscopic therapies and pharmacological interventions. Hospitals and specialty clinics are increasingly equipped to provide comprehensive GAVE management programs, improving patient outcomes across the country.

Asia-Pacific Gastric Antral Vascular Ectasia (GAVE) Treatment Market Insight

The Asia-Pacific gastric antral vascular ectasia (GAVE) treatment market is expected to be the fastest-growing region during the forecast period, with a CAGR of 9.1% from 2025 to 2032. Growth is driven by increasing urbanization, rising disposable incomes, and the expansion of healthcare facilities offering specialized gastrointestinal disorder management. Rising awareness among patients and physicians regarding effective treatment options, combined with government initiatives to strengthen healthcare infrastructure, is fueling market adoption across countries such as China, Japan, and India.

Japan Gastric Antral Vascular Ectasia (GAVE) Treatment Market Insight

The Japan gastric antral vascular ectasia (GAVE) treatment market is gaining momentum due to a high level of healthcare awareness, rapid urbanization, and demand for advanced diagnostic and therapeutic solutions. The country’s well-equipped medical facilities and specialized gastroenterology centers contribute to improved patient outcomes. An aging population, alongside increasing incidence of gastrointestinal disorders, is further driving the demand for early intervention and effective treatment options.

China Gastric Antral Vascular Ectasia (GAVE) Treatment Market Insight

The China gastric antral vascular ectasia (GAVE) treatment market accounted for the largest revenue share in Asia-Pacific in 2024. This growth is attributed to rapid urbanization, a growing middle-class population, and rising healthcare awareness. Expansion of hospitals and specialty care centers, alongside increasing adoption of modern diagnostic and endoscopic treatment technologies, is improving access to care. Government initiatives supporting gastrointestinal health and increasing investment in clinical research further strengthen the market’s growth prospects.

Gastric Antral Vascular Ectasia (GAVE) Treatment Market Share

The Gastric Antral Vascular Ectasia (GAVE) Treatment industry is primarily led by well-established companies, including:

• Olympus Corporation (Japan)
• Erbe Elektromedizin GmbH (Germany)
• PENTAX Medical (Japan)
• Boston Scientific Corporation (U.S.)
• FUJIFILM Corporation (Japan)
• Cook (U.S.)
• Medtronic (Ireland)
• HOYA Corporation (Japan)
• Richard Wolf GmbH (Germany)
• KARL STORZ (Germany)
• Stryker (U.S.)
• Smith+Nephew (U.K.)

Latest Developments in Global Gastric Antral Vascular Ectasia (GAVE) Treatment Market

• In May 2025, a case report published in Digestive Endoscopy highlighted the successful use of PuraStat, a novel self-assembling peptide hemostatic hydrogel, in treating a patient with GAVE. This approach was particularly beneficial for patients with contraindications to traditional therapies like argon plasma coagulation. The patient exhibited near-complete resolution of vascular ectasias at the 6-week follow-up
• In February 2025, a randomized clinical trial published in Endoscopy International Open compared the safety and efficacy of Endoscopic Band Ligation (EBL) and Argon Plasma Coagulation (APC) in managing GAVE. The study found that EBL demonstrated comparable efficacy to APC with a potentially safer profile, suggesting its growing role in endoscopic management of GAVE
• In January 2025, a case report published in Endoscopy described the combination of Endoscopic Band Ligation (EBL) with lauromacrogol injection as an effective treatment for GAVE. The patient showed a negative fecal occult blood test and normalization of hemoglobin levels at the 6-week follow-up, indicating the potential of this combined approach in managing GAVE
• In July 2023, a meta-analysis published in Clinical Endoscopy compared Endoscopic Band Ligation (EBL), Radiofrequency Ablation (RFA), and Endoscopic Thermal Therapy (ETT) for treating GAVE. The study concluded that EBL and RFA are effective alternatives to ETT, with EBL showing promising results in terms of safety and efficacy
• In March 2022, an article in Practical Gastroenterology discussed the evolving treatment landscape for GAVE, emphasizing the role of Endoscopic Band Ligation (EBL) as a promising alternative to traditional thermal therapies. The article highlighted the need for further research to establish standardized treatment protocols for GAVE

SKU-60766